The oncology division of the FDA has recently tightened regulations for expedited approvals and emphasised the significance of patient survival data. Several businesses promptly followed suit and withdrew questionable indicators when the agency applied more pressure. However, some businesses have made the decision to strike back. The first-in-class blood Cancer treatment Pepaxto from Oncopeptides and […]

The post FDA Examines 2 Other Cancer Approvals Without Revocation first appeared on World Pharma Today.